Phesgo and Tecentriq Performance and Approvals
Polivy in 1L DLBCL: FDA approval granted
Comprehensive NHL development program ongoing
Uptake in 1L DLBCL accelerating
NHL development program progressing
Roche
POLIVYⓇ
polatuzumab vedotin
1L DLBCL approved in >70 countries
Polivy quarterly sales
Indication
Regimen
Phl
Ph II
Ph III
CHF Mn
YoY CER growth
+96%
160
120
2L+ DLBCL (SCT ineligible) Polivy + R-GemOx
2L+ DLBCL (SCT ineligible) Lunsumio + Polivy
2L+ DLBCL (SCT ineligible) Columvi + GemOx
POLARGO
SUNMO
STARGLO
+89%
80
1L DLBCL
Columvi + Polivy + R-CHP
+20%
40
40
1L DLBCL (elderly unfit)
Lunsumio + Polivy
Approved
2L+ DLBCL (SCT ineligible) Columvi + Polivy
0
Q1 20
Q1 21
Q1 22
Q1 23
US
International
2L FL
Europe
Japan
• FDA ODAC voted 11-2 in favor of clinical benefit in 1L DLBCL
•
•
US approval granted with label for 1L DLBCL with IPI score 2-5
·
• US: Included in NCCN guideline as category 1*
•
UK: NICE reimbursement obtained**
Lunsumio+lenalidomide CELESTIMO
Ph III Columvi + Polivy + R-CHP in 1L DLBCL to be initiated in 2023
Ph III (SUNMO) Lunsumio + Polivy in 2L+ DLBCL to read out in 2023/24
•
Ph III (STARGLO) Columvi + GemOx in 2L+ DLBCL to read out in H2 2023
20
20
CER=constant exchange rates; NHL=Non-Hodgkin's lymphoma; DLBCL-diffuse large B-cell lymphoma; ODAC-oncologic drugs advisory committee; IPI=International prognostic index; FL-follicular lymphoma; R-GemOx=rituxan +
gemcitabine + oxaliplatin; R-CH(O)P=rituxan + cyclophosphamide + doxorubicin + (vincristine) + prednisone; *NCCN guidelines for B-Cell Lymphomas (V1.2023); **NICE: Polatuzumab vedotin in combination for untreated diffuse
large B-cell lymphoma [ID3901]; Polivy in collaboration with SeagenView entire presentation